COMMENTARY

Will Drug Makers Move to Pull Plug on Off-Patent Brands under “G1” Scheme?

March 12, 2018
By Takashi Ebisawa With Japan to significantly shave the NHI prices of off-patent brand-name medicines in its drug price revision next month, all eyes are now on whether pharma companies will move to pull their products off the market under…

To read the full story

Related Article

COMMENTARY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…